Head-to-head evidence
Carisbamate vs Oxcarbazepine (Oxtellar XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Carisbamate
Developed by SK Biopharmaceuticals Co., Ltd.
NCT00425282 · Phase 3 · completed
The study was randomized and double-blind with 566 participants, and its primary endpoint was the clinical measure of change in seizure frequency. However, no results are posted and the registry record does not clearly identify a comparator arm, so the primary endpoint cannot be judged as met or missed.
Next expected readout: February 2027 · NCT05219617 (registry estimate)
Oxcarbazepine (Oxtellar XR)
Marketed by Supernus Pharmaceuticals
NCT00772603 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Oxcarbazepine (Oxtellar XR)'s landscape